Search results
Showing 1711 to 1725 of 2548 results for methods
Discontinued Reference number: GID-TA11120
Carotuximab with pazopanib for treating advanced angiosarcoma [ID1503]
Discontinued Reference number: GID-TA10401
Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]
In development Reference number: GID-TA10598 Expected publication date: TBC
Discontinued Reference number: GID-TAG241
Bone loss (therapy-induced) in non-metastatic breast cancer - denosumab [ID83]
Discontinued Reference number: GID-TAG411
Avelumab for treating gastric or gastro-oesophageal junction cancer after 2 therapies ID1289
Discontinued Reference number: GID-TA10210
In development Reference number: GID-TA11345 Expected publication date: TBC
In development Reference number: GID-TAG386 Expected publication date: TBC
Dexmedetomidine for treating agitation associated with schizophrenia TS ID 10726
In development Reference number: GID-TA11015 Expected publication date: TBC
In development Reference number: GID-TA11014 Expected publication date: TBC
In development Reference number: GID-MT594 Expected publication date: TBC
Discontinued Reference number: GID-DT9
In development Reference number: GID-TA11523 Expected publication date: TBC
Pancreatic cancer (metastatic, untreated) - liposomal cisplatin (with gemcitabine) [ID658]
Discontinued Reference number: GID-TAG494
Cardiovascular disease: risk assessment and reduction, including lipid modification (NG238)
This guideline covers identifying and assessing risk of cardiovascular disease (CVD) in adults without established CVD. It covers lifestyle changes and lipid-lowering treatment (including statins) for primary and secondary prevention of CVD, and includes guidance for people who also have diabetes or chronic kidney disease.